Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema ( HAE ) at the 2024 ACAAI Annual Scientific Meeting
CAMBRIDGE, Mass., Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at ...
https://www.globenewswire.com/news-release/2024/09/12/2945086/0/en/Intellia-Therapeutics-to-Present-Data-from-the-Phase-2-Study-of-NTLA-2002-for-the-Treatment-of-Hereditary-Angioedema-HAE-at-the-2024-ACAAI-Annual-Scientific-Meeting.html